zandelisib

Zandelisib is an orally bioavailable, selective small molecule inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3Kδ). It is designed to block the PI3K/AKT signaling pathway by inhibiting PI3Kδ, which plays a key role in the proliferation and survival of hematologic cancer cells. This targeted inhibition decreases tumor cell proliferation and induces apoptosis in PI3Kδ-overexpressing tumor cells while aiming to preserve normal cell function. Zandelisib has been investigated primarily for B-cell malignancies such as relapsed or refractory follicular lymphoma and marginal zone lymphoma, with studies also including other indolent non-Hodgkin B-cell lymphomas. The drug was developed by Pathway Therapeutics and further advanced by MEI Pharma and Kyowa Kirin[1][2][4][5][6][7].

Other names

1401436-95-0